VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ HIV controlled on therapy for at least 12 weeks    │ HIV controlled on therapy for at least 12 weeks    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participants must be willing to comply with all    │ Participants must be willing to comply with all    │     100 │
│ study related procedures                           │ study related procedures                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Personal or family history of pancreatitis         │ Personal or family history of pancreatitis         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Medullary thyroid carcinoma (MTC) or Multiple      │ Medullary thyroid carcinoma (MTC) or Multiple      │     100 │
│ Endocrine Neoplasia Syndrome Type 2 (MEN 2)        │ Endocrine Neoplasia Syndrome Type 2 (MEN 2)        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Gastroparesis                                      │ Gastroparesis                                      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Allergy to liraglutide or any of the active        │ Allergy to liraglutide or any of the active        │     100 │
│ ingredients in liraglutide or other GLP-1 analogue │ ingredients in liraglutide or other GLP-1 analogue │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Weight loss drugs other than metformin             │ Weight loss drugs other than metformin             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Type 1 diabetes mellitus or diabetic ketoacidosis  │ Type 1 diabetes mellitus or diabetic ketoacidosis  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known major cognitive deficit dementia, history of │ Known major cognitive deficit dementia, history of │     100 │
│ head trauma with loss of consciousness \>30 min,   │ head trauma with loss of consciousness >30 min,    │         │
│ history of stroke, current central nervous system  │ history of stroke, current central nervous system  │         │
│ (CNS) disorder such as seizures or opportunistic   │ (CNS) disorder such as seizures or opportunistic   │         │
│ CNS infection                                      │ CNS infection                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active opportunistic infections                    │ Active opportunistic infections                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnancy or breastfeeding                         │ Pregnancy or breastfeeding                         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Unstable cardiovascular disease with               │ Unstable cardiovascular disease with               │     100 │
│ hospitalization within 1 year for acute coronary   │ hospitalization within 1 year for acute coronary   │         │
│ syndrome                                           │ syndrome                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Decompensated heart failure                        │ Decompensated heart failure                        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Substance abuse                                    │ Substance abuse                                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active alcohol or opioid substitution therapy      │ Active alcohol or opioid substitution therapy      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serious or unstable medical or psychological       │ Serious or unstable medical or psychological       │     100 │
│ conditions that would compromise the subject's     │ conditions that would compromise the subject's     │         │
│ safety for successful participation                │ safety for successful participation                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ BMI \>27 to 45                                     │ BMI >27 to 45                                      │      96 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Viral load \< 200 copies                           │ Viral load < 200 copies                            │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Diagnosis of DM type 2 with A1-C \>7 to 15         │ Diagnosis of DM type 2 with A1-C >7 to 15          │      99 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Renal insufficiency defined as creatinine          │ Renal insufficiency defined as creatinine          │      99 │
│ clearance \< 60 mL/min                             │ clearance < 60 mL/min                              │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria   │   Score │
╞═══════════════════════════════════╪═════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Substance abuse │      38 │
├───────────────────────────────────┼─────────────────┼─────────┤
│ Must have maximum age of 65 Years │ Substance abuse │      38 │
╘═══════════════════════════════════╧═════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 97
Average Levenshtein Ratio of individual lines: 94.0
OverAll Ratio: 95.5
